Seed · Medtech & Devices · Thame, United Kingdom · Founded 2022 · 11–50 employees
Signatur Biosciences develops precision diagnostic kits that transform standard qPCR machines into advanced tools for complex disease prognosis, starting with breast cancer. The company has secured high-profile recognition, being named one of MedCity’s Top Life Sciences Companies to Watch in 2025. It raised a US$7 million seed round on May 28, 2025, backed by Ion Beam Applications and Y Combinator. The startup is a spin-out from Imperial College and Oxford University and is building a decentralised diagnostics model with rapid and accessible results.
No open roles listed right now.